Lysine

Lysine

SCHEMBL659927

C[C@@H](O)[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.47
DPP7 Q9UHL4 7/20 0.36
DPP4 P27487 4/20 0.36
DPP8 Q6V1X1 3/20 0.36
DPP9 Q86TI2 2/20 0.36
FAP Q12884 1/20 0.34
THRB P10828 1/20 0.32
NOS3 P29474 2/20 0.32
NOS1 P29475 2/20 0.32
NOS2 P35228 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
ARG1 P05089 3/20 0.32
ARG2 P78540 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL27639977 1.00 GSR (0.47) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL17685564 0.97 GSR (0.43) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL8205468 0.97 GSR (0.43) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL28801803 0.94 GSR (0.41) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL4610561 0.94 GSR (0.41) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL29054307 0.93 GSR (0.40) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL10428569 0.92 GSR (0.39) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL3387882 0.92 GSR (0.48) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL21494166 0.92 GSR (0.48) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL21494167 0.92 GSR (0.48) GSRDPP7DPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2196202-B1 Lys-Pro-Thr and Lys-Pro as inflammation-inhibiting compounds LUGER THOMAS (DE) 2013-07-17 EP claimed
EP-2198723-B1 Inflammation inhibiting compounds LUGER THOMAS (DE) 2013-04-10 EP claimed
EP-1749524-B1 Inflammation-inhibiting compounds LUGER THOMAS (DE) 2011-03-23 EP claimed
EP-1427405-B1 INFLAMMATION-INHIBITING COMPOUNDS LUGER DR THOMAS (DE) 2007-04-04 EP claimed
US-9987372-B2 Phosphorylcholine conjugates and uses thereof TPCERA LTD. (IL) 2018-06-05 US disclosed
US-20170087202-A1 Inflammation Inhibiting Compounds LUGER THOMAS (DE) 2017-03-30 US disclosed
US-9550807-B2 Inflammation inhibiting compounds LUGER THOMAS (DE) 2017-01-24 US disclosed
US-20160193350-A1 Phosphorylcholine Conjugates and Uses Thereof TPCERA LTD. (IL) 2016-07-07 US disclosed
EP-2953978-A1 PHOSPHORYLCHOLINE CONJUGATES AND USES THEREOF Tel HaShomer Medical Research Infrastructure and Services Ltd. (IL) 2015-12-16 EP disclosed
US-9156881-B2 Tripeptide KDPT for antiapoptotic treatment WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) 2015-10-13 US disclosed
US-20150087578-A1 Inflammation Inhibiting Compounds LUGER THOMAS (DE) 2015-03-26 US disclosed
US-20140323394-A1 TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) 2014-10-30 US disclosed
EP-1117443-B1 PEPTIDE-BASED CARRIER DEVICES FOR STELLATE CELLS STICHTING TECH WETENSCHAPP (NL) 2005-11-02 EP disclosed
US-20050227916-A1 Peptide stellate carrier devices for stellate cells STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2005-10-13 US disclosed
US-6844319-B1 Peptide-based carrier devices for stellate cells STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2005-01-18 US disclosed
US-20040077552-A1 Inflammation-inhibiting compounds BRZOSKA, THOMAS (DE) 2004-04-22 US disclosed
EP-1117443-A1 PEPTIDE-BASED CARRIER DEVICES FOR STELLATE CELLS Stichting voor de Technische Wetenschappen (NL) 2001-07-25 EP disclosed
WO-2000023113-A1 PEPTIDE-BASED CARRIER DEVICES FOR STELLATE CELLS STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2000-04-27 WO disclosed
EP-0825999-A1 AMINES EXHIBITING ANALGESIC ACTION, THEIR PREPARATION AND USE L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) 1998-03-04 EP disclosed
WO-1996033210-A1 AMINES EXHIBITING ANALGESIC ACTION, THEIR PREPARATION AND USE L. MOLTENI & C. DEI FRATELLI ALITTI - SOCIETA' DI ESERCIZIO SOCIETA' PER AZIONI (IT) 1996-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087202-A1 Inflammation Inhibiting Compounds ARG1, IL1B, CTSH GSR 2443/4885DPP7 1088/4885DPP4 1006/4885
US-20040077552-A1 Inflammation-inhibiting compounds MIF, MRGPRX2, MRGPRX1 GSR 2277/4885DPP7 1277/4885DPP4 1360/4885
US-20150087578-A1 Inflammation Inhibiting Compounds ARG1, IL1B, CTSH GSR 2443/4885DPP7 1088/4885DPP4 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.